AJP - Endo Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 295: E238-E241, 2008. First published May 13, 2008; doi:10.1152/ajpendo.90394.2008
0193-1849/08 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/2/E238    most recent
90394.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheeseman, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheeseman, C.

REVIEWS

GLUT7: a new intestinal facilitated hexose transporter

Chris Cheeseman

Membrane Protein Research Group, Deparetment of Physiology, University of Alberta, Edmonton, Alberta, Canada

Submitted 24 April 2008 ; accepted in final form 6 May 2008

ABSTRACT

The very last member of the SLC2A gene family of facilitated hexose transporters to be cloned was SLC2A7 (hGLUT7). It has been assigned to the class II of the GLUT family on the basis of sequence similarity, and its closest family member is GLUT5, an intestinal fructose transporter. GLUT7 is primarily expressed in the small intestine and colon, although mRNA has been detected in the testis and prostate as well. The protein is expressed in the apical membrane of the small intestine and colon, and it has a high affinity (<0.5 mM) for glucose and fructose. The abundance of the protein in the small intestine does change in parallel with the dietary carbohydrate. However, the distribution of GLUT7 along the small intestine does not entirely match with the availability of glucose and fructose, suggesting that the physiological substrate for this transporter has yet to be identified. Unlike GLUT13, the proton-coupled myoinositol transporter (HMIT), there is no evidence for the coupling of protons to the hexose movement via GLUT7. One area of study in which GLUT7 has provided a useful comparison with GLUT1 has been in the development of the hypothesis that the facilitated hexose transporters may have a selectivity filter at the exofacial opening of the translocation pore, which helps to determine which hexoses can be transported. If substantiated, the elucidation of this mechanism may prove useful in the design of hexose analogs for use in cancer imaging and therapeutics.

glucose transporter proteins; SLC2A7; intestinal hexose absorption; structure-function


Cloning

THE LAST MEMBER OF THE SLC2A GENE FAMILY, which codes for the facilitative glucose transporter proteins (GLUTs), to be cloned was hGLUT7 (15). It had originally been identified from database analysis of the human genome sequence as a putative member of the second cluster (class II) of the GLUT proteins (human genomic contig AL356306 [GenBank] ). Prior to the sequencing of the human genome, the GLUT protein family had been limited to five members (GLUT1–5) with two additional pseudogene sequences, GLUT6 (13), a noncoding sequence, and a "GLUT7" (24). This latter protein appeared to be the putative endoplasmic reticular hexose transporter making up part of the glucose-6-phosphatase machinery. Subsequently this was shown to be a cloning artifact and withdrawn.

The bioinformatic analysis of the SCL2A gene family has shown that the 14 members fall into three clusters or classes on the basis of sequence similarity (12, 23). The second of these groups includes the intestinal fructose transporter GLUT5 (11), GLUT9 (21), GLUT11 (9), and, under the revised nomenclature, a putative GLUT7. Comparison of the GLUT5 cDNA sequence in the Genbank database (accession no. NM_003039) with the human contig (AL035703 [GenBank] in the NCBI database) allowed for the design of three pairs of forward and reverse primers, which were all based on a region conserved in both sequences. Given that GLUT5 had the closest sequence similarity to GLUT7, it was assumed that fructose was the likely substrate for this transporter, and cDNA libraries from tissues in which fructose was used as a metabolite (e.g., liver, kidney, and testes) were screened with these primers. However, this strategy initially led only to the identification of GLUT5. Finally, a human intestinal cDNA library proved to an excellent source, and a 0.8-kb cDNA sequence unique to GLUT7 was identified. Primers were then designed on the basis of this unique region, and the full-length sequence was initially identified as having 1,575 base pairs coding for 524 amino acids (15). However, the initial sequence lodged in the GenBank data base (AY571960 [GenBank] ) had 12 amino acids erroneously inserted in the first loop between transmembrane domains 1 and 2 (TM1 and -2). These have since been removed to give a protein of 512 amino acids, which has a sequence identity of 58.1% and similarity of 74.3% with GLUT5 (Fig. 1).


Figure 1
View larger version (18K):
[in this window]
[in a new window]

 
Fig. 1. Sequence alignment for hGLUT5 and hGLUT7. The two sequences were aligned using CLUSTALX software. Red highlights indicate the 12 putative transmembrane domains(TMs). Blue areas indicate the QQLS motif common to class I and II GLUTS in TM7; yellow indicates the hydrophobic NAI motif postulated to form part of an exofacial selectivity filter; green region shows the unique COOH-terminal sequence used to generate a specific GLUT7 polyclonal antibody.

 
Functional Activity

Injection of hGLUT7 cRNA into Xenopus oocytes resulted in a significant amount of the protein being expressed in the plasma membrane but the induction of a relatively low rate of hexose transport. Both glucose and fructose appeared to be substrates, while galactose, 2-deoxyglucose, and xylose were not. The kinetic analysis of the glucose and fructose transport showed a remarkably high affinity of the transporter for these substrates, with the Km as low as 200–300 µM. This is in sharp contrast with GLUT5, which has a Km for fructose of ~5–15 mM when expressed in oocytes or Chinese hamster ovary (CHO) cells (3, 11). The transport of hexoses by GLUT7 is not affected by the mycotoxin cytochalasin B (CB) or by phloretin, both of which can inhibit the activity of the class I and some of the class III GLUTs. Subsequent characterization of the other class II GLUTs indicates that none of them are sensitive to CB (19). Other substrates for this transporter have been screened, including short-chain fatty acids and urate (see Future Research below), but none have yet been found to be taken up by this protein (unpublished observations).

Sites of Expression

Northern blotting of human tissues indicated that the major sites of expression of GLUT7 mRNA appear to be in the small intestine and colon, with some RNA expressed in the testis and the prostate. Immunohistochemistry of rat tissue localized the protein to the apical membrane of the small intestinal epithelium in the upper (jejunum) and lower (ileal) regions, but apparently not in the colon. The duodenum has not been tested for expression. However, Western blotting of brush-border membranes showed expression of GLUT7 in all three regions, with similar levels of the protein in the jejunum and ileum and a little less in the colon (Fig. 2). Also, there was no evidence for the expression of mRNA or protein in the intestinal muscle. These findings were surprising given that the majority of carbohydrate digestion and absorption is achieved in the jejunum and completed by the end of the ileum. Thus, luminal concentrations of free hexoses in the ileum should be quite low and negligible in the colon. Furthermore, as a facilitative transporter, GLUT7 would be unlikely to move substrate against a concentration gradient from the lumen into the epithelial cells. However, the affinity for both glucose and fructose is extremely high, which would fit with the predicted low substrate concentrations in the ileal lumen.


Figure 2
View larger version (37K):
[in this window]
[in a new window]

 
Fig. 2. Effect of dietary carbohydrate on jejunal and ileal expression of GLUT7 in the rat. Animals were fed for 1 wk on normal rat chow (control), a low-carbohydrate (LC, 23%), or a high-carbohydrate (HC, 44%) diet. Isolated brush-border membranes were prepared from mucosal scrapings, and equivalent amounts of protein were loaded into SDS-PAGE gels. An antibody raised against the unique COOH-terminal sequence of GLUT7 (PTASPAKETSF) was used to detect the protein. A: Western blots of protein isolated from rat jejunum, ileum, and colon detecting GLUT7. B: relative abundance of GLUT7 determined by scanning Western blots and quantified using Un-Scan-It software. All data were normalized against the expression level of protein in the ileum from animals on the control diet. Error bars represent SE; aP < 0.05.

 
Control of Expression

The expression of hexose transporters in the small intestine changes in parallel with the abundance of their hexose substrates in the diet, so that both the facilitative (GLUTs) and concentrative [sodium-dependent glucose transporters (SGLTs)] increase or decrease when the carbohydrate intake is held at a particular level for several days (2, 7, 10). This also proved to be the case for GLUT7, the expression of which increased in the small intestine of rats when their dietary carbohydrate was increased using an isocaloric diet (Fig. 2). After 1 wk on a low- or a high-carbohydrate diet, in which the caloric content was kept constant by reciprocally changing the fat content, real-time PCR, Western blotting, and immunohistochemistry all indicated that both GLUT7 message and protein increased in animals on the high-carbohydrate diet. This would suggest that one or more of the recently published mechanisms for sensing luminal carbohydrate could also be responsible for the increase in transcription and subsequent translation of GLUT7 in the small intestine (16, 17, 20). In contrast, the expression of GLUT7 in the colon was unaffected by dietary carbohydrate, as would be expected given that normally no hexoses would reach that far down the GI tract. In the case of GLUT2 it has been shown that increased expression in the basolateral membranes (BLM) can be induced by either glucose or fructose in the diet, whereas nonmetabolized hexoses failed to induce a response (4). This induction appears to be controlled at the level of transcription in the small intestine (8). However, GLUT5 expression in the enterocyte apical membrane responds specifically to luminal fructose and not glucose (8). Currently, the control of GLUT7 expression in the intestine is limited to overall carbohydrate levels, and there have been no reported studies on the specificity of the signals involved (Fig. 3).


Figure 3
View larger version (7K):
[in this window]
[in a new window]

 
Fig. 3. Hexose transporter proteins expressed in intestinal enterocytes. There are ≤4 hexose transporters expressed in the apical membrane of intestinal epithelial cells (enterocytes). The sodium-coupled high-affinity glucose/galactose transporter SGLT1 and the facilitated fructose transporter GLUT5 are both expressed constitutively, although the level of SGLT1 can be acutely modulated up or down. The high-affinity glucose/fructose facilitative transporter GLUT7 is also expressed constitutively; possible regulation has not been determined. The low-affinity glucose/fructose facilitative transporter GLUT2 is transiently expressed in the apical membrane when luminal hexose concentrations are high. There appears to be only 1 facilitative hexose transporter, GLUT2, in the basolateral membrane. The activity of this transporter can be rapidly modulated by enteric peptide hormones.

 
Some hexose transporters in the small intestine can also be acutely regulated. GLUT2 activity in the BLM responds to increases in plasma and luminal glucose within 60 min (5, 22), and it has been proposed that this is mediated by the enteric peptide hormones gastric inhibitory polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) (6). GLP-2 has also been implicated in the rapid insertion of GLUT2 into the apical membrane (1), although this response appears to involve a complex set of signaling pathways including taste receptors, SGLT1, and apical calcium channels (14). Again, there is no information available on whether GLUT7 activity is also acutely responsive to vascular or luminal glucose levels or the hormones GIP and GLP-2.

Protein Structure

Like all the other GLUTs, hydropathy analysis indicated 12 membrane-spanning domains for GLUT7. The likely glycosylation site appears on the first extracellular loop between TMs 1 and -2, which is common for all of the class I and II GLUTs. Comparison of the sequence alignment of the other GLUT proteins indicated that, in the region predicted to form TM7, where a number of residues key to hexose transport had already been identified, there is a hydrophobic sequence that might correlate with substrate specificity. GLUT2, -5, -7, and -9 all transport fructose and express an isoleucine close to the exofacial end of TM7, whereas the non-fructose-transporting GLUTs GLUT1, -3, and -4 have a valine at this position. Expression of a GLUT7 mutant in which the isoleucine had been replaced with a valine resulted in a loss of fructose transport capacity, whereas glucose mediation was unaffected (18). This substitution was also found to result in the same loss of fructose transport, and the authors suggested that this residue (isoleucine or valine) might form a hydrophobic interaction across the exofacial opening of the translocation pore with a tryptophan in TM2. Furthermore, this structure might in some way form a substrate selectivity filter restricting hexose access to the translocation mechanism. Computer modeling of the structure of GLUT1 and -7 supported this contention, but in the absence of a crystal structure for these proteins it will be difficult to confirm whether this model is correct. However, it does raise interesting questions as to how this family of proteins recognizes their substrates and interacts with them during the transport cycle. Prior to the introduction of this hypothesis, it had been assumed that substrate specificity was determined solely by the substrate binding site(s) associated with the translocation mechanism. The conservation of this hydrophobic region at this position in the GLUT orthologs throughout numerous phyla suggests that this is an important structural component of facilitated hexose transporters (19).

Future Research

To date, the functional activity of GLUT7 has only been determined using the oocyte expression system, and its ability to mediate hexose transport in intestinal epithelial cells still needs to be assessed. The use of short interfering RNA to knock down the expression of GLUT7 or, alternatively, a mouse knockout model could provide useful insights into the contribution that this transporter makes to hexose absorption in the small intestine.

The physiological regulation of this transporter in the small intestine still remains to be elucidated. Is the transport activity or levels of expression regulated by the same or different signals and pathways from those for SGLT1, GLUT2, or GLUT5?

The very low capacity for glucose and fructose transport exhibited by GLUT7 does raise the possibility that the physiological substrate for this transporter is something other than a hexose. This transporter could exchange another organic compound for glucose or fructose. Recent findings with GLUT9 (23a), indicate that this closely related class II GLUT is a glucose-urate exchanger, and so GLUT7 may also interact with an as-yet-unidentified substrate.

Although Northern blotting has indicated the presence of GLUT7 message in the testis and prostate, the expression of the protein has not yet been measured in either of these tissues. Given the important metabolic role of fructose in these tissues, GLUT7 may well play an important role in providing metabolic substrate.

The structure-function studies with GLUT7 and, subsequently, other class II members, have raised an interesting possibility that GLUT proteins may have a substrate selectivity filter at the exofacial opening of their translocation pore. This putative structural element deserves further investigation because it could well have important implications for the design of hexose analogs used either for cell imaging with positron emission tomography (PET) or for possible cancer chemotherapeutic agents.

FOOTNOTES


Address for reprint requests and other correspondence: C. Cheeseman, Membrane Protein Research Group, Dept. of Physiology, Univ. of Alberta, Edmonton, Alberta, T6G 2H7, Canada (e-mail: chris.cheeseman{at}ualberta.ca)

REFERENCES

  1. Au A, Gupta A, Schembri P, Cheeseman CI. Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2. Biochem J 367: 247–254, 2002.[CrossRef][Web of Science][Medline]
  2. Burant CF, Saxena M. Rapid reversible substrate regulation of fructose transporter expression in rat small intestine and kidney. Am J Physiol Gastrointest Liver Physiol 267: G71–G79, 1994.[Abstract/Free Full Text]
  3. Burant CF, Takeda J, Brot-Laroche E, Bell GI, Davidson NO. Fructose transporter in human spermatozoa and small intestine is GLUT5. J Biol Chem 267: 14523–14526, 1992.[Abstract/Free Full Text]
  4. Cheeseman CI, Harley B. Adaptation of glucose transport across rat enterocyte basolateral membrane in response to altered dietary carbohydrate intake. J Physiol 437: 563–575, 1991.[Abstract/Free Full Text]
  5. Cheeseman CI, Maenz DD. Rapid regulation of Na-independent D-glucose transport in the basolateral membrane of rat jejunum. Am J Physiol Gastrointest Liver Physiol 256: G878–G883, 1989.[Abstract/Free Full Text]
  6. Cheeseman CI, Tsang R. The effect of gastric inhibitory polypeptide and glucagon-like peptides on intestinal hexose transport. Am J Physiol Gastrointest Liver Physiol 271: G477–G482, 1996.[Abstract/Free Full Text]
  7. Corpe CP, Burant CF. Hexose transporter expression in rat small intestine: effect of diet on diurnal variations. Am J Physiol Gastrointest Liver Physiol 271: G211–G216, 1996.[Abstract/Free Full Text]
  8. Cui XL, Soteropoulos P, Tolias P, Ferraris RP. Fructose-responsive genes in the small intestine of neonatal rats. Physiol Genomics 18: 206–217, 2004.[Abstract/Free Full Text]
  9. Doege H, Bocianski A, Scheepers A, Axer H, Eckel J, Joost HG, Schürmann A. Characterization of human glucose transporter (GLUT) 11 (encoded by SLC2A11), a novel sugar-transport facilitator specifically expressed in heart and skeletal muscle. Biochem J 359: 443–449, 2001.[CrossRef][Web of Science][Medline]
  10. Dyer J, Hosie KB, Shirazi-Beechey SP. Nutrient regulation of human intestinal sugar transporter (SGLT1) expression. Gut 41: 56–95, 1997.[Abstract/Free Full Text]
  11. Inukai K, Katagiri H, Takata K, Asano T, Anai M, Ishihara H, Nakazaki M, Kikuchi M, Yazaki Y, Oka Y. Characterization of rat GLUT5 and functional analysis of chimeric proteins of GLUT1 glucose transporter and GLUT5 fructose transporter. Endocrinology 136: 4850–4857, 1995.[Abstract]
  12. Joost HG, Bell GI, Best JD, Birnbaum MJ, Charron MJ, Chen YT, Doege H, James DE, Lodish HF, Moley KH, Moley JF, Mueckler M, Rogers S, Schürmann A, Seino S, Thorens B. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab 282: E974–E976, 2002.[Abstract/Free Full Text]
  13. Kayano T, Burant CF, FukumotoH, Gould GW, Fan YS, Eddy RL, Byers MG, Shows TB, Seino S, Bell GI. Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNAs encoding an isoform (GLUT5) expressed in small intestine, kidney, muscle, and adipose tissue and an unusual glucose transporter pseudogene-like sequence (GLUT6). J Biol Chem 265: 13276–13282, 1990.[Abstract/Free Full Text]
  14. Kellett GL, Brot-Laroche E, Mace OJ, Leturque A. Sugar absorption in the intestine: the role of GLUT2. Annu Rev Nutr PMID: 1839 3659, Epub ahead of print Apr 7, 2008.
  15. Li Q, Manolescu A, Ritzel M, Yao S, Slugoski M, Young JD, Chen XZ, Cheeseman CI. Cloning and functional characterization of the human GLUT7 isoform SLC2A7 from the small intestine. Am J Physiol Gastrointest Liver Physiol 287: G236–G242, 2004.[Abstract/Free Full Text]
  16. Le Gall M, Tobin V, Stolarczyk E, Dalet V, Leturque A, Brot-Laroche E. Sugar sensing by enterocytes combines polarity, membrane bound detectors and sugar metabolism. J Cell Physiol 213: 834–843, 2007.[CrossRef][Web of Science][Medline]
  17. Mace OJ, Affleck J, Patel N, Kellett GL. Sweet taste receptors in rat small intestine stimulate glucose absorption through apical GLUT2. J Physiol 582: 379–392, 2007.[Abstract/Free Full Text]
  18. Manolescu A, Salas-Burgos AM, Fischbarg J, Cheeseman CI. Identification of a hydrophobic residue as a key determinant of fructose transport by the facilitative hexose transporter SLC2A7 (GLUT7). J Biol Chem 280: 42978–42983, 2005.[Abstract/Free Full Text]
  19. Manolescu AR, Witkowska K, Kinnaird A, Cessford T, Cheeseman C. Facilitated hexose transporters: new perspectives on form and function. Physiology (Bethesda) 22: 234–240, 2007.[CrossRef][Medline]
  20. Margolskee RF, Dyer J, Kokrashvili Z, Salmon KS, Ilegems E, Daly K, Maillet EL, Ninomiya Y, Mosinger B, Shirazi-Beechey SP. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci USA 104: 15075–15080, 2007.[Abstract/Free Full Text]
  21. Phay JE, Hussain HB, Moley JF. Cloning and expression analysis of a novel member of the facilitative glucose transporter family, SLC2A9 (GLUT9). Genomics 66: 217–220, 2000.[CrossRef][Web of Science][Medline]
  22. Tsang R, Ao Z, Cheeseman CI. The influence of luminal and vascular hexoses on intestinal basolateral glucose transport. Can J Physiol Pharmacol 72: 317–326, 1994.[Web of Science][Medline]
  23. Uldry M, Thorens B. The SLC2 family of facilitated hexose and polyol transporters. Pflügers Arch 447: 480–489, 2004.[CrossRef][Web of Science][Medline]
  24. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu X, Janicijevic B, Smolej-Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A, Donnelly LA, Fairbanks LD, Aringer M, McKeigue PM, Ralston SH, Morris AD, Rudan P, Hastie ND, Campbell H, Wright AF. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 40: 437–442, 2008.[CrossRef][Web of Science][Medline]
  25. Waddell ID, Zomerschoe AG, Voice & Burchell A MW. Cloning and expression of a hepatic microsomal glucose transport protein. Comparison with liver plasma-membrane glucose-transport protein GLUT 2. Biochem J 286: 173–177, 1992.[Web of Science][Medline]



This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
B. Thorens and M. Mueckler
Glucose transporters in the 21st Century
Am J Physiol Endocrinol Metab, February 1, 2010; 298(2): E141 - E145.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. J. Fisher, P. W. Swaan, and N. D. Eddington
The Ethanol Metabolite Acetaldehyde Increases Paracellular Drug Permeability In Vitro and Oral Bioavailability In Vivo
J. Pharmacol. Exp. Ther., January 1, 2010; 332(1): 326 - 333.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S. Schmidt, H.-G. Joost, and A. Schurmann
GLUT8, the enigmatic intracellular hexose transporter
Am J Physiol Endocrinol Metab, April 1, 2009; 296(4): E614 - E618.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Schurmann
Insight into the "odd" hexose transporters GLUT3, GLUT5, and GLUT7
Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E225 - E226.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/2/E238    most recent
90394.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheeseman, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheeseman, C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.